Vimarsana
Biggest News Aggregation in the World

Page 7 - Probe Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Probe Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Probe Development Today - Breaking & Trending Today

Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility - Vimarsana News

Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility. The facility, to be built by McMaster and equipped and validated by Fusion, will be designed to support manufac

Source: yahoo.com
CPDC Announces Appointment of Bruno Paquin as Permanent CEO - Vimarsana News

CPDC Announces Appointment of Bruno Paquin as Permanent CEO

CPDC Announces Appointment of Bruno Paquin as Permanent CEO News provided by Share this article Share this article HAMILTON, ON, March 10, 2021 /PRNewswire/ - The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Bruno Paquin as Chief Executive Officer (CEO). The CEO appointment has taken effect on March 4, 2021.  Dr. John Thornback, Chair of the Board of Directors said, "W e are pleased to announce that Bruno Paquin has been appointed CEO of CPDC with immediate effect. The Board feels that Bruno has done an excellent job as inter...

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007 - Vimarsana News

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Published: Feb 24, 2021   HAMILTON, ON, Feb. 24, 2021 /PRNewswire/ - The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [ 18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that targets Prostate Specific Membrane Antigen (PSMA), a protein that is overexpressed in prostate cancer. Prostate cancer is the most common malignancy in Canadian men, accountin...

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007 - Vimarsana News

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

/PRNewswire/ - The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of...

In Canada, shippers race to move cancer treatments as COVID-19 grounds flights - Vimarsana News

In Canada, shippers race to move cancer treatments as COVID-19 grounds flights

4 Min Read MONTREAL/TORONTO (Reuters) - Medical companies and shippers in Canada are racing to transport time-sensitive radiochemical materials used to treat cancer, as a pandemic-induced drop in passenger flights has narrowed transportation options and created cargo delays. FILE PHOTO: An American Airlines cargo plane is unloaded at Philadelphia International Airport in Philadelphia, Pennsylvania, U.S., December 4, 2020. REUTERS/Rachel Wisniewski/File Photo Half of air cargo normally travels in the belly of passenger jets rather than dedicated freighters. But flight cancellations as traffic ...